{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:47Z","timestamp":1792266707716,"version":"4.4.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with relapsed\/refractory (R\/R) Hodgkin lymphoma (HL), achieving a complete metabolic response (CMR) after salvage therapy is associated with superior outcomes, and optimal treatments must be identified. The combination of brentuximab vedotin and bendamustine (BVB), although highly active in adult patients, has not been extensively evaluated in pediatric patients with R\/R HL. We performed a multicenter, retrospective review of pediatric patients &amp;lt;21 years of age with R\/R HL treated with BVB from January 2016 through July 2019. Response was assessed by local radiologists according to Lugano classification criteria. Twenty-nine patients (17 relapsed, 12 refractory) with a median age of 16 years (range, 10-20) were treated with BVB and received a median of 3 cycles of therapy (range, 2-7). Patients received an infusion of 1.8 mg\/kg of BV on day 1 with bendamustine 90 mg\/m2 on days 1 and 2 of 3-week cycles. Nineteen patients (66%) achieved a CMR (95% CI, 46-82). An objective response was observed in 23 patients (objective response rate, 79%; 95% CI, 60-92). The most common grade 3 and 4 toxicities were hematologic, and 3 patients (10%) experienced grade 3 infusion reactions. Seventeen of 18 patients underwent successful mobilization and collection of stem cells. Sixteen patients (13 autologous, 3 allogeneic) received a consolidative transplant after BVB. The 3-year post-BVB event-free and overall survival were 65% (95% CI, 46-85) and 89% (95% CI, 74-100), respectively. For pediatric patients with R\/R HL, BVB was well tolerated and compared favorably with currently accepted salvage regimens.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005268","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:04:09Z","timestamp":1632499449000},"page":"5519-5524","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed\/refractory Hodgkin lymphoma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1206","authenticated-orcid":false,"given":"Christopher J.","family":"Forlenza","sequence":"first","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9243-9544","authenticated-orcid":false,"given":"Nitya","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6093","authenticated-orcid":false,"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Absalon","sequence":"additional","affiliation":[{"name":"Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Franklin","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders, Children\u2019s Hospital Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Keller","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"issue":"16","key":"2021121716302342700_B1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer."},{"issue":"32","key":"2021121716302342700_B2","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021121716302342700_B3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425 [published correction appears in Blood. 2016;128(4):605]","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood."},{"issue":"8","key":"2021121716302342700_B4","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1080\/10428194.2017.1403601","article-title":"Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience","volume":"59","author":"Giulino-Roth","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"25","key":"2021121716302342700_B5","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin\u2019s disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group","volume":"23","author":"Schellong","year":"2005","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021121716302342700_B6","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood."},{"issue":"7","key":"2021121716302342700_B7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2021121716302342700_B8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pbc.24851","article-title":"Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma","volume":"61","author":"Harker-Murray","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2021121716302342700_B9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.13388","article-title":"A phase 2 study of bortezomib in combination with ifosfamide\/vinorelbine in paediatric patients and young adults with refractory\/recurrent Hodgkin lymphoma: a Children\u2019s Oncology Group study","volume":"170","author":"Horton","year":"2015","journal-title":"Br J Haematol."},{"issue":"1","key":"2021121716302342700_B10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pbc.25205","article-title":"Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory\/relapsed Hodgkin lymphoma, AHOD00P1: a children\u2019s oncology group report","volume":"62","author":"Trippett","year":"2015","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"2021121716302342700_B11","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","article-title":"Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin\u2019s disease: a children\u2019s oncology group report","volume":"27","author":"Cole","year":"2009","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021121716302342700_B12","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol."},{"issue":"9","key":"2021121716302342700_B13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"2021121716302342700_B14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021121716302342700_B15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood."},{"issue":"2","key":"2021121716302342700_B16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"2021121716302342700_B17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","article-title":"First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi","volume":"9","author":"Broccoli","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"2021121716302342700_B18","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/bjh.17274","article-title":"The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series","volume":"192","author":"McMillan","year":"2021","journal-title":"Br J Haematol."},{"issue":"6","key":"2021121716302342700_B19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz","year":"2010","journal-title":"Br J Haematol."},{"issue":"1","key":"2021121716302342700_B20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00043426-200101000-00008","article-title":"Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children\u2019s cancer group report","volume":"23","author":"Cairo","year":"2001","journal-title":"J Pediatr Hematol Oncol."},{"issue":"12","key":"2021121716302342700_B21","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol."},{"issue":"18","key":"2021121716302342700_B22","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021121716302342700_B23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.12120","article-title":"Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma","volume":"160","author":"Corazzelli","year":"2013","journal-title":"Br J Haematol."},{"issue":"4","key":"2021121716302342700_B24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021121716302342700_B25","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3109\/10428194.2013.776165","article-title":"Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients","volume":"54","author":"Ghesqui\u00e8res","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2021121716302342700_B26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.12821","article-title":"Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi","volume":"166","author":"Anastasia","year":"2014","journal-title":"Br J Haematol."},{"issue":"23","key":"2021121716302342700_B27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.5099.5099","article-title":"Bendamustine monotherapy is effective as salvage therapy in patients with refractory\/relapsed pediatric Hodgkin lymphoma (HL): a retrospective analysis [abstract]","volume":"126","author":"Tandon","year":"2015","journal-title":"Blood."},{"key":"2021121716302342700_B28","article-title":"Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed\/refractory classical Hodgkin lymphoma [abstract]","volume":"132","author":"H","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2021121716302342700_B29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer."},{"issue":"10","key":"2021121716302342700_B30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.clml.2017.06.033","article-title":"Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies","volume":"17","author":"Penne","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"2","key":"2021121716302342700_B31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021121716302342700_B32","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjh.14667","article-title":"Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma","volume":"178","author":"Martin","year":"2017","journal-title":"Br J Haematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5519\/1853743\/advancesadv2021005268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5519\/1853743\/advancesadv2021005268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T09:55:35Z","timestamp":1699523735000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/24\/5519\/477032\/Combination-brentuximab-vedotin-and-bendamustine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":32,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005268","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}